Clinical trials: Hospital-acquired Pneumonia, open to volunteers
Hospital Acquired Pneumonia
Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype
Determine the efficacy of dexamethasone plus standard of care (SOC) as compared to placebo plus SOC for treating severe hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype; It's an…
- Trial name
- HAP-DEX (NCT06269900)
- Testing
- Dexamethasone
- Where
- 34 sites in France, Greece and 1 more
- Volunteers
- 450 people
- Sponsor
- Nantes University Hospital
Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection
A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea
The purpose of this study is to learn about the safety and effectiveness of Zavicefta once released into the markets in Korea. This study is to learn about Zavicefta in patients with difficult types of infections in the abdomen…
- Conditions
- Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection, Hospital-acquired Pneumonia
- Trial name
- NCT05733104
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Pfizer
Hospital-acquired Pneumonia (HAP), Ventilator-Associated Pneumonia (VAP)
Resistance-Optimised Antimicrobial Dosing in Critically Ill Patients, a Randomised Controlled Trial
Critically ill people who need a breathing machine often develop hospital-acquired lung infections. These infections are commonly treated with the antibiotics piperacillin/tazobactam or meropenem.
- Conditions
- Hospital-acquired Pneumonia (HAP), Ventilator-Associated Pneumonia (VAP), Nosocomial Respiratory Infection, Critical Illness
- Trial name
- ROAD-RCT (NCT07820501)
- Testing
- Resistance-Optimised Precision Dosing, Standard Care Dosing
- Volunteers
- 610 people
- Sponsor
- The University of Queensland
Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP
This study is to evaluate the efficacy and safety of Meropenem and Pralurbactam for Injection in Subjects with HABP/VABP. The primary objective is to demonstrate non-inferiority of Meropenem and Pralurbactam to Ceftazidime and…
- Trial name
- NCT07327619
- Testing
- Meropenem and Pralurbactam, Ceftazidime-avibactam
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Ventilator-Associated Pneumonia (VAP), Central Line-Associated Bloodstream Infection
Impact of Nurses' Behavior Change and Evidence-Based Practice Implementation on Quality Indicators in Intensive Care Units in Low- and Middle-Income Countries
Study title: Impact of nurses' behavior change and implementing evidence-based practice to improve quality indicators in intensive care units in low-and middle-income countries Background and Rationale: Quality care is crucial…
- Conditions
- Ventilator-Associated Pneumonia (VAP), Central Line-Associated Bloodstream Infection, Pressure Ulcers (Hospital-acquired Pressure Injuries), Prolonged Intensive Care Unit Length of Stay
- Trial name
- NCT07397364
- Testing
- Evidence based practices bundles of care
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Cairo University
Pneumonia, Ventilator-Associated, Pneumonia, Hospital-Acquired
Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Immunocompromised Patients With Hospital-acquired Pneumonia Requiring Mechanical Ventilation
RESPIRE is a randomized, unblinded, controlled study to measure the impact of a strategy based on a PCR test on the adjustment of antimicrobial therapy in immunocompromised patients suspected with ventilator-associated or…
- Conditions
- Pneumonia, Ventilator-Associated, Pneumonia, Hospital-Acquired, Immunodeficiency
- Trial name
- RESPIRE (NCT05405491)
- Testing
- PCR based strategy, Standard care
- Where
- France
- Volunteers
- 31 people
- Sponsor
- University Hospital, Lille
Hospital-acquired Pneumonia, Antibiotic Resistant Infection
Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment
The goal of this prospective and observatory study is to learn about the pathogen, clinical manifestations, prognosis, treatment and antibiotic resistance of bacteria in hospital-acquired pneumonia patients in China.
- Trial name
- CHAPTER (NCT06028217)
- Testing
- prognosis status
- Volunteers
- 4,000 people
- Sponsor
- Ruijin Hospital
Coronary Artery Disease, Pneumonia Nosocomial
Nosocomial Pneumonia After Coronary Artery Bypass Grafting
Observational studies of patients with coronary artery bypass grafting, associated with an unfavorable cardiopulmonary prognosis for at least one year after surgery.
- Trial name
- CABG-PNEUM (NCT07476274)
- Testing
- Clinical, laboratory, and instrumental examination
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Nosocomial Infection, Nosocomial Pneumonia
Mechanical Insufflation-exsufflation and Hypertonic Saline in Nosocomial Bacterial Respiratory Tract Infection
Multicenter, randomized open label clinical trial to evaluate IEM and HS as concomitant therapy for respiratory tract infection in patients under artificial ventilation in the ICU.
- Conditions
- Nosocomial Infection, Nosocomial Pneumonia, Tracheobronchitis, Mechanical Ventilation Complication
- Trial name
- ABSENTA (NCT06310941)
- Testing
- Mechanical insufflation-exsufflation, Standard of Care, Hypertonic saline with hyaluronic acid
- Where
- 8 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Hospital San Carlos, Madrid
Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia
A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex
This is a phase 2a, multinational, multicenter, double-blind, randomized, placebo-controlled, dose-ranging safety, tolerability and PK study in patients with HABP (Hospital Acquired Bacterial Pneumonia) or VABP (Ventilator…
- Trial name
- NCT06087536
- Testing
- OMN6
- Where
- 15 sites in Greece, Israel
- Volunteers
- 54 people
- Sponsor
- Omnix Medical Ltd
Infectious Disease of Lung, Molecular Diagnosis
Clinical Impact of a Multiplex Rapid Diagnostic Pneumonia Panel Testing in Critically-ill Patients With Severe Hospital-acquired Pneumonia, Ventilator-associated Pneumonia and Community-acquired Pneumonia With High Risk of Multidrug Resistant Pathogen
The objective of the research is to ascertain the influence of a syndromic mutiplex PCR assay (FilmArray) on the management of patients hospitalised in the ICU for severe respiratory disease.
- Conditions
- Infectious Disease of Lung, Molecular Diagnosis, Pneumonia
- Trial name
- NCT06782607
- Testing
- Pneumonia Panel by FilmArray
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Mahidol University
Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP)
Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
This is a Phase 3, randomized, double-blind, multicenter, comparative study evaluating cefepime-zidebactam (FEP-ZID) versus ceftazidime-avibactam (CAZ-AVI) with or without colistin in the treatment of adults with…
- Trial name
- NCT07885891
- Testing
- Cefepime-Zidebactam, Ceftazidime-avibactam with or without Colistin
- Where
- 55 sites in Bosnia and Herzegovina, Bulgaria and 12 more
- Volunteers
- 324 people
- Sponsor
- Wockhardt
Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP)
Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
This Phase IIb study aims to evaluate the safety and efficacy of BV100 in combination with low dose polymyxin B plus ceftazidime/avibactam or cefiderocol in patients with suspected or confirmed CRABC infections.
- Conditions
- Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP), Blood Stream Infection, Meningitis, Bacterial
- Trial name
- RIV- CARE (NCT07431307)
- Testing
- BV100 with 50 mg polymyxin B plus ceftazidime/avibactam, BV100 with 50 mg polymyxin B plus cefiderocol, Best Available Therapy (BAT)
- Volunteers
- 120 people
- Sponsor
- BioVersys AG
Pneumonia - Bacterial
Impact of BioFire FilmArray Pneumonia Panel vs Routine Diagnostics on Antimicrobial Outcomes (DOOR-MAT)
Multidrug-resistant bacterial infections are a growing global health concern. Hospital-acquired pneumonia is one of the most common infections occurring during hospitalization and can be associated with high mortality, reaching…
- Trial name
- NCT07585604
- Testing
- Multiplex PCR-based pneumonia panel (BIOFIRE® FILMARRAY® Pneumonia Panel)
- Where
- Brazil
- Volunteers
- 150 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Pneumonia, Viral, Ventilator Associated Pneumonia
Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL
Almost 90 out of 100 people carry herpes simplex viruses (HSV). Once a person has been infected with the herpes viruses, he or she can't get rid of them for the rest of her/his life.
- Conditions
- Pneumonia, Viral, Ventilator Associated Pneumonia, Community-acquired Pneumonia, Herpes Simplex
- Trial name
- HerpMV (NCT06134492)
- Testing
- Acyclovir
- Where
- 28 sites in Germany
- Volunteers
- 616 people
- Sponsor
- Jena University Hospital
Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
The study will evaluate the efficacy and safety of Meropenem and Pralurbactam versus Best Available Therapy in the treatment of Carbapenem-Resistant Enterobacteriaceae Infections.
- Conditions
- Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP), Complicated Intra-abdominal Infection (cIAI), Complicated Urinary Tract Infection (cUTI)
- Trial name
- NCT07089186
- Testing
- Meropenem and Pralurbactam, Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Hospital Acquired Pneumonia
Predictors and Outcomes of Ventilated Hospital-acquired Pneumonia
Hospital-acquired pneumonia (HAP) is defined as an infection of the pulmonary parenchyma that develops in patients admitted to hospital for more than 48 hours and that was not incubating at the time of admission.
- Trial name
- NCT07667582
- Testing
- mechanical ventilation (MV)
- Where
- Egypt
- Volunteers
- 151 people
- Sponsor
- Assiut University
Pneumonia, Sepsis
Study of Progression of Community Acquired Pneumonia in the Hospital in Patients With More Severe Preexisting Diseases and Immunosuppression
Pneumonia is a common infectious disease of the lung, often requiring treatment in the hospital. Clinical scoring systems are available, identifying patients not requiring hospitalization.
- Conditions
- Pneumonia, Sepsis, Shock, Septic
- Trial name
- PROGRESSCOMORB (NCT05688774)
- Where
- 10 sites in Germany
- Volunteers
- 300 people
- Sponsor
- Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps
Hospital Acquired Pneumonia (HAP), Cardiovascular and Respiratory Disease
Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia
The HOMI-LUNG - HAP study is part of the HOMI-LUNG project, funded by the Horizon Europe program. The "HOMI-LUNG" project is an international, interdisciplinary project that aims to better understand the causal links between…
- Trial name
- HOMI-LUNG-HAP (NCT06602934)
- Testing
- Blood samples, Oropharyngeal swabs, ECG
- Where
- 5 sites in France
- Volunteers
- 300 people
- Sponsor
- Nantes University Hospital
Community-Acquired Pneumonia, Pediatric Pneumonia
Clinical Predictors of Severity in Pediatric Community-Acquired Pneumonia at Assiut University Children's Hospital
This study aims to identify the clinical factors that predict the severity of community-acquired pneumonia (CAP) in pediatric patients.
- Conditions
- Community-Acquired Pneumonia, Pediatric Pneumonia, Lower Respiratory Tract Infection
- Trial name
- CAP-Severity (NCT07279675)
- Testing
- Assessment of Pneumonia Severity
- Volunteers
- 67 people
- Sponsor
- Assiut University